Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Cappuzzo, F. [1 ]
Moreno Garcia, V. [2 ]
Ou, S-H. I. [3 ]
Brandao, M. [4 ]
Sanmamed, M. F. [5 ]
Helissey, C. [6 ]
Wislez, M. [7 ]
Call, J. A. [8 ]
Grisanti, S. [9 ]
Johnson, M. L. [10 ]
Boni, V. [11 ]
Jamme, P. [12 ]
Monnet, I. [13 ]
Siena, S. [14 ]
Yan, C. [15 ]
Barasa, B. [16 ]
Richard, B. [17 ]
Joe, A. K. [18 ]
Laus, G. [18 ]
Felip, E. [19 ]
机构：
[1] IRCCS Ist Nazl Tumori Regina Elena IRE, Med Oncol, Rome, Italy
[2] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD Early Phase Clin Trials Unit, Madrid, Spain
[3] UCI Hlth Chao Family Comprehens Canc Ctr, Med Dept, Orange, CA USA
[4] Inst Jules Bordet, Med Oncol Dept, Brussels, Belgium
[5] Clin Univ Navarra, Oncol Dept, Pamplona, Spain
[6] Begin Mil Teaching Hosp, Clin Res Unit, St Mande, France
[7] Hop Cochin AP HP, Paris, France
[8] South Texas Accelerated Res Therapeut START, Phase Trials, San Antonio, TX USA
[9] Univ Brescia, Med Oncol Dept, Brescia, Italy
[10] Sarah Cannon Res Inst, Lung Canc Res, Canc Ctr, Nashville, TN USA
[11] Hosp Univ Quironsalud Madrid, Oncol Dept, Pozuelo De Alarcon, Spain
[12] Ctr Hosp Reg Univ Lille, CHU Lille, Haut France, Lille, France
[13] CHI Creteil, Creteil, France
[14] Univ Milano Statale, UNIMI, Hematooncol Dept, Milan, Italy
[15] Merus NV, Biostat, Utrecht, Netherlands
[16] Merus NV, Translat Res, Utrecht, Netherlands
[17] Merus NV, Clin Operat, Utrecht, Netherlands
[18] Merus NV, Clin Dev, Utrecht, Netherlands
[19] Vall Hebron Univ Hosp, Lung Canc Unit, Med Oncol Serv, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
516MO
引用
收藏
页码：S1671 / S1671
页数：1
相关论文
共 50 条
  • [21] Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
    Popat, Sanjay
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 192 - 193
  • [22] Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment
    Tanaka, Saki
    Tamiya, Motohiro
    Nishiuma, Satoshi
    Nakamura, Sayaka
    Nozaki, Keisuke
    Watanabe, Naoko
    Itoh, Chisae
    Kadokawa, Yukio
    Takeda, Kenji
    Takahashi, Kozo
    Miyazaki, Akito
    Kawamura, Takahisa
    Kunimasa, Kei
    Inoue, Takako
    Nishino, Kazumi
    Takagi, Mari
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 40
  • [23] SAFETY OF TEPOTINIB plus OSIMERTINIB IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) WITH MESENCHYMAL-EPITHELIAL TRANSITION (MET) AMPLIFICATION FOLLOWING FIRST-LINE OSIMERTINIB: INSIGHT 2 PRIMARY ANALYSIS
    Le, Xiuning
    Hamm, John
    Deligo, James T.
    Berghoff, Karin
    Wu, Yi-Long
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [24] Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Zhong, R.
    Zhong, H.
    Zhang, B.
    Zhang, W.
    Shi, C.
    Qian, J.
    Han, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S129 - S129
  • [25] Local Ablative Therapy for Oligoprogressive, EGFR-Mutant, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib
    Kim, C.
    Roper, N.
    Hoang, C.
    Connolly, M.
    Cultraro, C.
    Szabo, E.
    Waris, M.
    Padiernos, E.
    Kesarwala, A.
    Gao, S.
    Steinberg, S.
    Wong, D.
    Khan, J.
    Rajan, A.
    Guha, U.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2146 - S2146
  • [26] Local ablative therapy for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib
    Kim, Chul
    Roper, Nitin
    Chuong Hoang
    Wisch, Laura
    Connolly, Maureen
    Chou, Hsien-Chao
    Wei, Jun
    Tyagi, Manoj
    Cultraro, Constance M.
    Xi, Liqiang
    Waris, Maryam
    Khoa Dang Nguyen
    Szabo, Eva
    Padiernos, Emerson
    Kesarwala, Aparna
    Gao, Shaojian
    Steinberg, Seth M.
    Raffeld, Mark
    Rajan, Arun
    Khan, Javed
    Guha, Udayan
    CANCER RESEARCH, 2018, 78 (13)
  • [27] INDIRECT COMPARISON OF EFFICACY AND SAFETY FOR AUMOLERTINIB VS OSIMERTINIB IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Stergiopoulos, S.
    King, S.
    Curtis, M.
    Dillon, S. A.
    Akehurst, R.
    Lee, D.
    Guelfucci, F.
    Ngami, A.
    Bianic, F.
    Li, Y.
    Ma, X.
    Ali, S.
    Miller, V. A.
    Popat, S.
    VALUE IN HEALTH, 2022, 25 (12) : S42 - S42
  • [28] First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status
    Takamizawa, Shigemasa
    Okuma, Yusuke
    Kato, Yasuhiro
    Hakozaki, Taiki
    Kitagawa, Shingo
    Zenke, Yoshitaka
    FUTURE ONCOLOGY, 2021, 18 (03) : 291 - 300
  • [29] Afatinib vs. Osimertinib as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer Harboring EGFR Mutations
    Hoang, T. T. A.
    Nguyen, T. T. T.
    Pham, C. T. M.
    Dong, H. Q.
    Nguyen, K. T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S626 - S627
  • [30] Response: Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR Tyrosine Kinase Inhibitor Therapy
    Wu, Bin
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (05) : E84 - E85
12345